Syndax Pharmaceuticals’ (SNDX) Buy Rating Reiterated at B. Riley
Syndax Pharmaceuticals (NASDAQ:SNDX)‘s stock had its “buy” rating reaffirmed by equities research analysts at B. Riley in a research report issued to clients and investors on Thursday. They currently have a $40.00 target price on the stock. B. Riley’s price target points to a potential upside of 337.64% from the stock’s current price.
Separately, Zacks Investment Research lowered Syndax Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, November 11th. One equities research analyst has rated the stock with a sell rating and nine have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $24.38.
Syndax Pharmaceuticals (SNDX) traded down $0.07 during mid-day trading on Thursday, hitting $9.14. The stock had a trading volume of 139,400 shares, compared to its average volume of 249,409. Syndax Pharmaceuticals has a fifty-two week low of $6.31 and a fifty-two week high of $15.70. The firm has a market capitalization of $222.92 and a price-to-earnings ratio of -3.23.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. FMR LLC grew its stake in Syndax Pharmaceuticals by 7.3% during the 2nd quarter. FMR LLC now owns 1,341,644 shares of the company’s stock valued at $18,743,000 after purchasing an additional 91,328 shares in the last quarter. Vanguard Group Inc. grew its stake in Syndax Pharmaceuticals by 25.1% during the 2nd quarter. Vanguard Group Inc. now owns 512,624 shares of the company’s stock valued at $7,161,000 after purchasing an additional 102,700 shares in the last quarter. JPMorgan Chase & Co. grew its stake in Syndax Pharmaceuticals by 11,266.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 439,070 shares of the company’s stock valued at $6,134,000 after purchasing an additional 435,207 shares in the last quarter. Alyeska Investment Group L.P. grew its stake in Syndax Pharmaceuticals by 1.8% during the 3rd quarter. Alyeska Investment Group L.P. now owns 330,910 shares of the company’s stock valued at $3,872,000 after purchasing an additional 5,910 shares in the last quarter. Finally, Tekla Capital Management LLC acquired a new stake in Syndax Pharmaceuticals during the 2nd quarter valued at approximately $2,794,000. Hedge funds and other institutional investors own 61.65% of the company’s stock.
WARNING: This piece of content was reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this piece of content on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://theolympiareport.com/2018/01/18/syndax-pharmaceuticals-sndx-buy-rating-reiterated-at-b-riley.html.
About Syndax Pharmaceuticals
Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Company’s product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from its Phase IIb clinical trial, ENCORE 301, is being evaluated in a Phase III clinical trial for advanced hormone receptor positive breast cancer.
Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.